CD52 antibody | YTH34.5

100% Secure

Anti Human CD52 Antibody, clone YTH34.5 thumbnail image 1

Anti Human CD52 Antibody, clone YTH34.5 thumbnail image 2

Anti Human CD52 Antibody, clone YTH34.5 thumbnail image 3

Anti Human CD52 Antibody, clone YTH34.5 thumbnail image 4

Anti Human CD52 Antibody, clone YTH34.5 gallery image 1 — Figure A. Pacific Blue conjugated mouse anti human CD3 (MCA463PB) and RPE conjugated rat IgG2b isotype control (MCA6006PE). Figure B. Pacific Blue conjugated Mouse anti Human CD3 (MCA463PB) and RPE conjugated mouse anti human CD52 (MCA1642PE). All experiments performed on red cell lysed human blood gated on lymphocytes in the presence of 10% human serum. Data acquired on the ZE5™ Cell Analyzer.

Anti Human CD52 Antibody, clone YTH34.5 gallery image 2 — **Published customer image:**
Rat anti Human CD52 antibody, clone YTH34.5 (**MCA1642**) used for staining lymphoma tissue specimens by immunohistochemistry on formalin fixed, paraffin embedded sections.
**Image caption:**
Positive CD52 IHC from representative DHL cases reveals a range of staining intensities: 1+ (A), 2+ (B), and 3+ (C). H&E stain of the strongly CD52-positive DHL case depicted in C (D). Many cases exhibited uniform staining intensity (E), while others showed variable CD52 expression (F).

From: Craig JW, Mina MJ, Crombie JL, LaCasce AS, Weinstock DM, Pinkus GS, *et al*. (2018)
Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.
PLoS ONE 13(7): e0199708.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.

Anti Human CD52 Antibody, clone YTH34.5 gallery image 3 — **Published customer image:**
FITC conjugated Mouse anti Human CD52 antibody, clone YTH34.5 (**MCA1642F**) used for the evaluation of CD52 expression on human cell lines by flow cytometry.
**Image caption:**
WM-specific antigen expression compared across RPCI-WM1, BCWM.1 and MWCL-1 cell lines.
Fluorescein (FITC), phycoerythrin (PE), phycoerythrin—cyanine 5 (PC5) or allophycocyanin (APC) conjugates of various antibodies were used as presented above. All cell lines were negative for CD10 and 11c. Blue line indicates RPCI-WM1 antigen expression, red line indicates MWCL-1 antigen expression and green line indicates antigen expression in BCWM.1 cell line. Only BCWM.1 an MWCL-1 were CD19+, CD20+ and FMC7+. Expression of CD138 and κ-light-chain was seen only on MWCL-1 and RPCI-WM1 cells. CD28 expression was markedly more observable on RPCI-WM1 tumor cells as compared to MWCL-1 or BCWM.1.

From: Paulus A, Chitta KS, Wallace PK, Advani PP, Akhtar S, Kuranz-Blake M, *et al*. (2015)
Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications.
PLoS ONE 10(4): e0122338.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.

Anti Human CD52 Antibody, clone YTH34.5 gallery image 4 — **Published customer image:**
FITC conjugated Mouse anti Human CD52 antibody, clone YTH34.5 (**MCA1642F**) used for the evaluation of CD52 expression on RPCI-WM1 cells by flow cytometry.
**Image caption:**
Expression of WM-specific antigens present on RPCI-WM1.
For antigen detection, fluorescein (FITC), phycoerythrin (PE), phycoerythrin—cyanine 5 (PC5) or allophycocyanin (APC) conjugates of various antigen-specific antibodies were used. Flow cytometry shows the RPCI-WM1 cell line to be CD10, 11c, 19, 20, 23, 27, 40, 52 and 79b negative and CD22, 28, 38, 45, 45RO, 38, 138, κ light chain and intracellular-κ positive.

From: Paulus A, Chitta KS, Wallace PK, Advani PP, Akhtar S, Kuranz-Blake M, *et al*. (2015)
Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications.
PLoS ONE 10(4): e0122338.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.

Rat anti Human CD52:FITC

Rat anti Human CD52:Low Endotoxin

Rat anti Human CD52

Rat anti Human CD52:RPE

Product Type: Monoclonal Antibody
Clone: YTH34.5
Isotype: IgG2b

Product Code	Applications	Pack Size
MCA1642FT	F	25 µg
MCA1642F	F	0.1 mg
MCA1642EL	C CT E F IP P RE WB	0.5 mg
MCA1642T	C F P RE	20 µg
MCA1642	C CT E F IP P RE WB	0.2 mg
MCA1642PET	F	25 Tests/0.25ml
MCA1642PE	F	100 Tests

Rat anti Human CD52 antibody, clone YTH34.5 reacts with the human CD52 antigen, also known as CAMPATH-1. The CD52 antigen is a remarkably small but heavily glycosylated peptide attached to the cell surface membrane via a GPI link (Xia et al. 1991).

The apparent molecular mass of the native antigen on SDS-PAGE is 25-29kDa, considerably reduced following N-glycanase treatment (Rowan et al. 1998).

CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.

Humanized versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies (Dearden et al. 2002; Pettitt et al. 2012).

Product Details

Target Species

Human

Species Cross-Reactivity

Target Species	Cross Reactivity
Rhesus Monkey

N.B. Antibody reactivity and working conditions may vary between species.

Product Form

Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid

Product Form

Purified IgG - liquid

Product Form

Purified IgG - liquid

Product Form

Pack Size: 25 Tests/0.25ml

Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilised

Pack Size: 100 Tests

Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized

Reconstitution

Pack Size: 25 Tests/0.25ml

Reconstitute with 0.25ml distilled water

Pack Size: 100 Tests

Reconstitute with 1 ml distilled water

Preparation

Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant

Preparation

Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant

Preparation

Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant

Preparation

Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant

Buffer Solution

Phosphate buffered saline

Buffer Solution

Phosphate buffered saline

Buffer Solution

Phosphate buffered saline

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.09%	Sodium Azide
1%	Bovine Serum Albumin

Preservative Stabilisers

None present

Preservative Stabilisers

0.09%

Sodium Azide

Preservative Stabilisers

Pack Size: 25 Tests/0.25ml

0.09%	Sodium Azide
1%	Bovine Serum Albumin
5%	Sucrose

Pack Size: 100 Tests

0.09%	Sodium Azide
1%	Bovine Serum Albumin
5%	Sucrose

Immunogen

Human lymphocytes.

Approx. Protein Concentrations

IgG concentration 0.1 mg/ml

Approx. Protein Concentrations

IgG concentration 1.0 mg/ml

Approx. Protein Concentrations

IgG concentration 1.0 mg/ml

Storage Information

Storage: Pack Size: 25 µg
Store at +4^oC or at -20^oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Pack Size: 0.1 mg
Store at +4^oC or at -20^oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage: Store at -20^oC only.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage: Store at +4^oC or at -20^oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage: Pack Size: 25 Tests/0.25ml
Prior to reconstitution store at +4^oC.
After reconstitution store at +4^oC.
DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.

Pack Size: 100 Tests
Prior to reconstitution store at +4^oC. Following reconstitution store at +4^oC.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee: 18 months from date of despatch.
Guarantee: 18 months from date of despatch.
Guarantee: 18 months from date of despatch.
Guarantee: 12 months from date of reconstitution.

More Information

UniProt: P31358 Related reagents
Entrez Gene: CD52 Related reagents
GO Terms: GO:0005887 integral to plasma membrane; GO:0005624 membrane fraction; GO:0007204 elevation of cytosolic calcium ion concentration; GO:0031225 anchored to membrane; GO:0045730 respiratory burst
Regulatory: For research purposes only

Applications of CD52 antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

Application Name	Min Dilution	Max Dilution
Flow Cytometry		Neat
Cytotoxic Assays		50ug/ml (Use human serum as complement source)
ELISA
Flow Cytometry	1/50	1/100
Immunohistology - Frozen
Immunohistology - Paraffin
Immunohistology - Resin
Immunoprecipitation
Western Blotting
Cytotoxic Assays		50ug/ml (Use human serum as complement source)
ELISA
Flow Cytometry		1/20
Immunohistology - Frozen		1/20
Immunohistology - Paraffin	1/20	1/20 Pack Size: 20 µg 1/40 Pack Size: 0.2 mg
Immunohistology - Resin
Immunoprecipitation
Western Blotting
Flow Cytometry	Neat	Neat Pack Size: 25 Tests/0.25ml 1/2 Pack Size: 100 Tests

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Flow Cytometry: Use 10ul of the suggested working dilution to label 10⁶ cells or 100ul whole blood.
Flow Cytometry: use 10ul of the suggested working dilution to label 1 x 10⁶ cells in 100ul.
Flow Cytometry: use 10ul of the suggested working dilution to label 1 x 10⁶ cells in 100ul.
Flow Cytometry: Use 10ul of the suggested working dilution to label 1 x 10⁶ cells in 100ul
Histology Positive Control Tissue: Tonsil
Histology Positive Control Tissue: Tonsil

Secondary Antibodies Available

Description	Product Code	Pack Size	Applications
Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed)	STAR131A	1 ml	C E P WB
Goat anti Rat IgG:Biotin (Mouse Adsorbed)	STAR131B	0.5 mg	C E IF P WB
Rabbit F(ab')2 anti Rat IgG:Dylight®800	STAR16D800GA	0.1 mg	F IF WB
Rabbit F(ab')2 anti Rat IgG:FITC	STAR17B	1 mg	F
Rabbit F(ab')2 anti Rat IgG:HRP	STAR21B	1 mg	C E P RE
Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed)	STAR69	0.5 ml	F
Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed)	STAR71D800GA	0.1 mg	F IF WB
Goat anti Rat IgG:HRP (Mouse Adsorbed)	STAR72	0.5 mg	C E P
Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed)	STAR73	0.5 ml	F
Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed)	STAR131A	1 ml	C E P WB
Goat anti Rat IgG:Biotin (Mouse Adsorbed)	STAR131B	0.5 mg	C E IF P WB
Rabbit F(ab')2 anti Rat IgG:Dylight®800	STAR16D800GA	0.1 mg	F IF WB
Rabbit F(ab')2 anti Rat IgG:FITC	STAR17B	1 mg	F
Rabbit F(ab')2 anti Rat IgG:HRP	STAR21B	1 mg	C E P RE
Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed)	STAR69	0.5 ml	F
Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed)	STAR71D800GA	0.1 mg	F IF WB
Goat anti Rat IgG:HRP (Mouse Adsorbed)	STAR72	0.5 mg	C E P
Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed)	STAR73	0.5 ml	F

Negative Isotype Controls Available

Description	Product Code	Pack Size	Applications
Rat IgG2b Negative Control:FITC	MCA6006F	0.1 mg	F
Rat IgG2b Negative Control:Low Endotoxin	MCA6006EL	0.5 mg	F
Rat IgG2b Negative Control	MCA6006GA	0.1 mg	F
Rat IgG2b Negative Control:RPE	MCA6006PE	100 Tests	F

Useful Reagents Available

Description	Product Code	Pack Size	Applications
Human Seroblock	BUF070A	50 Test	F
Human Seroblock	BUF070B	200 Test	F
Human anti Alemtuzumab	HCA174	0.1 mg	E
Human anti Alemtuzumab	HCA175	0.1 mg	E
Human Seroblock	BUF070A	50 Test	F
Human Seroblock	BUF070B	200 Test	F

Application Based External Images

Flow Cytometry

Immunohistology - Paraffin

Product Specific References

References for CD52 antibody

Hale G et al. (1998) Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Blood. 92 (12): 4581-90.
Salisbury JR et al. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
J Clin Pathol. 47 (4): 313-7.
Rodig SJ et al. (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Clin Cancer Res. 12 (23): 7174-9.
Haniffa, M. et al. (2009) Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation.
J Exp Med. 206: 371-85.
Ratzinger, G. et al. (2003) Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
Blood. 101: 1422-9.
Hu, Y. et al. (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Immunology. 128: 260-70.
Golay, J. et al. (2006) The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
Haematologica. 91: 322-30.
Klangsinsirikul, P. et al. (2002) Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
Blood. 99: 2586-91.
Piccaluga, P.P. et al. (2007) Expression of CD52 in peripheral T-cell lymphoma.
Haematologica. 92: 566-7.
Gopcsa, L. et al. (2005) Extensive flow cytometric characterization of plasmacytoid dendritic cell leukemia cells.
Eur J Haematol. 75: 346-51.
Chang, S.T. et al. (2007) CD52 expression in non-mycotic T- and NK/T-cell lymphomas.
Leuk Lymphoma. 48: 117-21.
Westermann, J. et al. (2005) CD52 is not a promising immunotherapy target for most patients with multiple myeloma.
Int J Hematol. 82: 248-50.
Reimer, P. et al. (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.
J Clin Oncol. 27: 106-13.
Zand, M.S. et al. (2005) A renewable source of donor cells for repetitive monitoring of T- and B-cell alloreactivity.
Am J Transplant. 5: 76-86.
Rizzo, K. et al. (2009) Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation.
Cytometry B Clin Cytom. 76: 142-9.
Miles, R.R. et al. (2007) Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report.
Br J Haematol. 138: 506-12.
Bisig, B. et al. (2013) Molecular and phenotypic features are shared by CD30-positive peripheral T-cell lymphomas
Haematologica 98: 1250-8.
Hotta, R. et al. (2016) CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
PLoS One. 11 (8): e0161618.
Buckstein, R. et al. (2016) Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.
Clin Lymphoma Myeloma Leuk. 16 (1): 18-28.e4.
Craig, J.W. et al. (2018) Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.
PLoS One. 13 (7): e0199708.
Paulus, A. et al. (2015) Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.
PLoS One. 10 (4): e0122338.

View more products with CD52 specificity